Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
zdravilo mabthera so uporabili pri 21 bolnikih po avtologni transplantaciji kostnega mozga in pri drugih rizičnih skupinah, pri katerih je pričakovano zmanjšano delovanje kostnega mozga, ne da bi se pojavila mielotoksičnost.
mabthera has been used in 21 patients who underwent autologous bone marrow transplantation and other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
intravensko obliko zdravila mabthera so uporabili pri 21 bolnikih po avtologni transplantaciji kostnega mozga in pri drugih rizičnih skupinah, pri katerih je pričakovano zmanjšano delovanje kostnega mozga, ne da bi se pojavila mielotoksičnost.
the mabthera intravenous formulation has been used in 21 patients who underwent autologous bone marrow transplantation and other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
zaradi morebitnih aditivnih farmakodinamskih učinkov (mielotoksičnost) se priporoča previdnost, saj se zaradi sočasne uporabe lahko povečata nevarnost in stopnja resnosti hematološke toksičnosti zdravila teysuno.
however, due to possible additive pharmacodynamic effects (myelotoxicity), caution is advised as co- administration may increase the risk and severity of haematologic toxicity of teysuno.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
mielotoksičnost je bila reverzibilna v 4 do 6 tednih po prekinitvi protivirusne terapije za hcv in sočasnega azatioprina in se po ponovni uvedbi enega od obeh zdravljenj ni ponovila (glejte poglavje 4.5).
this myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of hcv antiviral therapy and concomitant azathioprine and did not recur upon re-introduction of either treatment alone (see section 4.5).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
kadar najvišji dovoljeni odmerek ni dosežen, se prehodna mielotoksičnost pojavi pri manj kot 10 % bolnikov, medtem ko lahko pri najvišjem dovoljenem odmerku pride do reverzibilne depresije kostnega mozga pri več kot 50 % bolnikov.
when the maximum tolerated dose is not reached transient myelotoxicity usually occurs in less than 10% of patients, while under the maximum tolerated dose more than 50% can experience reversible bone marrow suppression.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: